Erratum

This article refers to:

Review of palonosetron: emerging data distinguishing it as a novel 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting

In the drug evaluation “Review of palonosetron: emerging data distinguishing it as a novel 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting” by Saito and Tsukuda, published in the April 2010 issue of Expert Opinion on Pharmacotherapy (Expert Opin. Pharmacother. (2010) 11(6):1003-1014), on page 1005, Table 1 should have appeared as follows:

Table 1. History of antiemetics.

Year	–1989	1990–	1995–	2000–	2005–	2009–
Guideline MASCC			1998 MASCC HEC 5-HT3RA + Dexamethasone + Metochlopramide MEC 5-HT3RA + Dexamethasone	2004 MASCC HEC NK-1 RA + 5-HT3RA + Dexamethasone MEC 5-HT3RA + Dexamethasone		2009 MASCC HEC/AC NK-1 RA + 5-HT3RA* + Dexamethasone MEC excluding AC palonosetron + Dexamethasone
Guideline NCCN					2006- NCCN HEC/AC NK-1 RA + 5-HT3RA + Dexamethasone MEC excluding AC 5-HT3RA + Dexamethasone	2009- NCCN HEC Palonosetron is preferred in 5-HT3RAs
Emetogenicity of chemotherapy			5 levels by emetic risk > 90% 60 – 90% 30 – 60% 10 – 30% < 10%	4 levels Highly (> 90%) Moderately (30 – 90%) Low (10 – 30%) Minimum (< 10%)		AC is similar to HEC
Goal of CINV control	Acute emesis			Delayed emesis		Overall emesis Nausea
Antiemetics
	Dex +dopamine RA or metochlopramide			Dex: Effective both acute and delayed phase (meta-analysis)
	5-HT3RA 1st generation Ondansetron Granisetron Dolasetron Tropisetron		1st generations 5-HT3RAs are equivalent	2nd generation palonosetron		Superiority of palonosetron to granisetron in delayed phase with dexamethasone
					NK-1 RA Aprepitant

*If NK-1RA is not available, palonosetron is preferred in AC.

5-HT3RA: 5-hydroxytryptamine 3 receptor antagonist; AC: Combination chemotherapy of anthracycline and cyclophosphamide; Dex: Dexamethasone; HEC: Highly emetogenic chemotherapy; MASCC: Multinational association of supportive care in cancer; MEC: Moderately emetogenic chemotherapy; NCCN: National Comprehensive Cancer Society; NK-1RA: Neurokinin-1 receptor antagonist.

The authors and publisher sincerely regret any inconvenience that this may have caused.